TP53 and acute myeloid leukemia: In the case of AML (sample 7), OGM identified a complex rearrangement on chromosome 17 involving the deletion of the TP53 gene, while NGS detected a pathogenic splice site alteration (TP53c.97-1G>T; Tier 1A classification) (Figure 5b).